5: Session 4: Disease-modification studies: Are we ready to start? 2nd Advanced ECCO: EduCational COurse for Industry
2016
1
62: Best abstract: Drug-concentration versus symptom-driven dose adaptation of infliximab in patients with active Crohn’s Disease: A prospective, randomised, multicentre trial (Tailorix)ECCO'16 Amsterdam
2016
1
6: Case based discussion: Investigation and management of mild/moderate Crohn’s Disease14th IBD Intensive Advanced Course
2016
1
6: IBD as a primary immune cell deficiency: Neutrophils and complementMolecular aetiology of IBD
2016
1